Study of Molecular Markers in Cutaneous Inflammation Between Psoriatic Lesional Skin and Healthy Non-lesional Skin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-11

Study Completion Date

2019-07-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The project topic consists on re-conciliating the fine tuners of the gene expression "microRNAs" and the immunopathogenic occasions responsible for skin disorders in context of skin infection and inflammation such as psoriasis. The skin is a network of effector cells and molecular mediators that constitute a highly sophisticated "Skin Immune System (SIS) described by Jan D Bos in 1986. The cutaneous homeostasis maintenance is dependent on the cross talk between several immune sentinels present in the different compartments of the skin as well as the interplay between innate and adaptive immune responses. The whole is under the control of gene regulation. However, cutaneous homeostasis disruption occurs when the SIS safe framework erroneously sends aggravation signals due to gene regulation disbalance via inflammatory cellular and molecular mediators into the site of infection causing chronic inflammation characterized by thick red irritated skin lesions. The latter was showed to have a characteristic microRNA (regulators of gene expression) signature.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

NCT06599411

Atopic Dermatitis Psoriasis Hidradenitis Suppurativa +7 more

NOT_YET_RECRUITING

Analysis of Cytokine Expression Pattern in Systemic Sclerosis

NCT03537105

Systemic Sclerosis

COMPLETED NA

Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata

NCT03976622

Vitiligo Psoriasis Alopecia Areata +1 more

UNKNOWN

Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis.

NCT03559465

Scleroderma, Systemic

COMPLETED NA

Cellular and Molecular Biomarkers in Patients With Lichen Planus

NCT06451744

Lichen Planus

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient with lesional skin

the sample will be taken by superficial cutaneous biopsy in psoriasic patients

Group Type EXPERIMENTAL

Biopsy

Intervention Type PROCEDURE

the sample will be taken by superficial cutaneous biopsy in psoriasic patients

Patients with healthy skin

the skin will be recovered during a surgical procedure (surgical waste) for patients who will not be opposed

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biopsy

the sample will be taken by superficial cutaneous biopsy in psoriasic patients

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or women between 18 and 75
* Clinical diagnosis of chronic active psoriasis in non-pustular plaque
* Treated locally with topical corticosteroids

Exclusion Criteria

* Patient who did not give express consent to participate
* No affiliation to a social security scheme
* Patient treated systemically
* Thrombocytopenic patient
* Patient known to be HIV-positive
* Septic patient
* Patient with only facial lesions
* Patient with psoriasis with joint involvement
* Patient participating in another study
* Patient protected under the law (under guardianship or trusteeship)
* Pregnant or lactating woman

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No